As our weekend here in Washington D.C. draws to an end, we turn our spotlight on an important and timely conversation from the "Sponsoring Women in Science" session. In this episode, we sit down with Dr. Elizabeth Volkmann and Dr. Carol Feghali-Bostwick to explore the challenges women face in advancing their careers in the sciences. Our guests share insights on how to address the barriers that often impede career development for women, discuss strategies for fostering support and mentorship, and highlight the importance of growing awareness around these critical issues.

Get ready for an electrifying episode of Convergence 2024! We're diving deep into the cutting-edge world of autoinflammatory diseases with renowned experts Drs. Grant Schulert and Arthur Kaser. Join us as they unravel the complexities of refractory and complicated systemic juvenile idiopathic arthritis (SJIA). Discover the revolutionary insights into SJIA at the single-cell level, explore the fascinating transcriptional diversity of normal and low-density granulocytes, and learn how groundbreaking approaches like UDON and SATAY-UDON are paving the way for novel disease programs. Don't miss this chance to fuel your passion for innovation in medicine—tune in and ignite your curiosity!

This week we're joined by two leading experts in gout remissions, Dr. Nicola Dalbeth and Dr. Dansoa Tabi-Amponsah to explore the exciting advances in gout treatment, with a particular focus on Dual-Energy CT (DECT) imaging and its role in achieving gout remission. We dive into how DECT technology is transforming our ability to visualize urate crystals in joints, its implications for patient care, and the potential it holds for long-term gout management and remission.

In another installment in the ongoing Arthritis & Rheumatology immunology series, guest David S. Pisetsky, MD, PhD, author of Unique Interplay Between Antinuclear Antibodies and Nuclear Molecules in the Pathogenesis of Systemic Lupus Erythematosus, takes us on a deep dive into research in SLE on how the combination of ANAs and immunologically active DNA can create new structures that can promote inflammation throughout the body as well as drive organ inflammation and damage.

This week, our next guest, ACR Master Dr. Joan T. Merrill, joins us to discuss her latest study which endeavored to evaluate the efficacy and safety of upadacitinib and elsubrutinib in those with systemic lupus erythematosus (SLE). Join us for an in-depth analysis of the SLEek Study, its findings regarding the efficacy of these medications and Dr. Merrill's conclusions.

For those with rheumatic disease, everyday challenges can mean an increase in disease flare. However, research is increasingly pointing to the idea that psychosocial stressors could even heighten the risk of developing rheumatic diseases. Dr. Christine Parks looked deeper into this among those with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) in her latest study Life Events, Caregiving, and Risk of Autoimmune Rheumatic Diseases in the Women's Health Initiative Observational Study

This week, we explore a groundbreaking study on the prevalence of fibromyalgia and widespread pain in patients with psoriatic arthritis with first author and ACR Master, Dr. Philip J. Mease. In his latest article, titled: Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association with Disease Severity Assessment in a Large US RegistryUID , Dr. Mease explains what the presence of these conditions reveals about disease severity and how they converge.

As the dawn of the Ai revolution marches on, scientific research and clinical medicine are adopting new and more streamlined ways to investigate and serve our patients. Today, we look at how Ai-driven, large language models (LLMs) might aid our field's researchers in analyzing data from patient interviews. Dr. Bella Mehta, corresponding author of A Novel Approach for Mixed-Methods Research Using Large Language Models: A Report Using Patients' Perspectives on Barriers to Arthroplasty , joins us this week to give us her insights on this this quickly evolving technology and how it can be employed in both the research and clinical setting.

Genetic conditions, inherited personality traits, brain chemistry...these are but a few of the well-known biological determinants of health and are but a small sample of factors that can determine how severe disease may affect a patient. But what role can social factors play in determining a patient's health? What of the 'Social Determinants of Health (SDoH)'? Dr. Shivani Garg set out to identify these factors and understand how they play a role in determining the severity of symptoms in those with Lupus Nephritis (LN). What she discovered was that not only do these factors play a significant role, but each one added has a multiplicative effect on the patient's reported outcome! Dr. Garg is our guest today and her study, published in Arthritis Care & Rheumatology titled: Multiplicative Impact of Adverse Social Determinants of Health on Outcomes in Lupus Nephritis: A Meta-analysis and Systematic Review, will be the focus of our discussion.

The process of weaning our patients off biologic disease-modifying antirheumatic drug (b-DMARD) therapy is not unfamiliar in our clinics. However, when attending to our patients, many complications and questions arise. Specific guidance is needed, but where do we turn? Thankfully, our latest guest, Dr. Paul Emery, may have some answers. His latest study, Predicting Flare in Patients With Rheumatoid Arthritis in Biologic Induced Remission, on Tapering, and on Stable Therapy attempted to "identify predictors of flare in patients in stable b-DMARD–induced clinical remission". Let's dive in together and see what he and his team have found!